• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE® EXCLUDER® AAA ENDOPROSTHESIS; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE® EXCLUDER® AAA ENDOPROSTHESIS; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT Back to Search Results
Catalog Number PLC271000
Medical Device Problem Code Insufficient Device Problem Information (3190)
Health Effect - Clinical Codes Aneurysm expansion (4597); Clinical Endoleak (4843)
Date of Event 08/09/2023
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
H6: code c19 - a review of the manufacturing records indicated the lot met all pre-release specifications.H6: code b20 -the device remains implanted and was therefore not available for engineering evaluation by gore.According to the gore® excluder® aaa endoprosthesis instructions for use (ifu), potential adverse events that may occur and/or require intervention include, but are not limited to aneurysm enlargement, endoleak, and reoperation.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
 
Event or Problem Description
The following was reported to gore: on (b)(6) 2019, the patient underwent an endovascular (evar) procedure to treat abdominal aorta aneurysm (aaa) utilizing gore® excluder® aaa endoprosthesis (trunk ipsilateral leg c3 and two contralateral legs).One of the contralateral legs, a plc271000 limb was used to seal the right common iliac artery.The initial result was successful.During follow ups, the aaa sac had grown.The ct scan measurements were 63.7 mm x 54.5 mm on (b)(6) 2021 and 71.7 mm x 64.3 mm on (b)(6) 2023.The right common iliac artery appeared to be degenerating around the plc271000 contralateral limb.Reportedly, it was felt there was an endoleak, but unable to tell if it was a type 1b or type 2.An angiogram was performed recently (date unknown) that did not clearly show an endoleak.Due to the growth and suspicion of a type 1b on the right side, the physician decided to bring the patient back for a reintervention procedure and that it would take care of the endoleak, if it were actually present.On (b)(6) 2023, the patient underwent an endovascular zone 10 common iliac revision procedure with a right sided gore® excluder® iliac branch endoprosthesis (ibe) placement into the prior evar with gore® viabahn® vbx balloon expandable endoprosthesis (vbx) stenting from the ibe gate into the right internal iliac artery.The procedure was well tolerated and without complication with the successful exclusion of the probable right sided type 1b endoleak.They will have to follow the sac size with cta surveillance to truly know if this solved the issue.
 
Additional Manufacturer Narrative
Added b7, g3/g4, and h1/h2.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE® EXCLUDER® AAA ENDOPROSTHESIS
Common Device Name
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL SILICON VALLEY B/P
2890 de la cruz blvd.
santa clara CA 95050
Manufacturer Contact
jaskaran parhar
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key17595947
Report Number3013164176-2023-01807
Device Sequence Number6535260
Product Code MIH
UDI-Device Identifier00733132618538
UDI-Public00733132618538
Combination Product (Y/N)N
Initial Reporter StatePA
Initial Reporter CountryUS
PMA/510(K) Number
P020004
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2019
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Company Representative
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 08/24/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date01/07/2022
Device Catalogue NumberPLC271000
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 08/09/2023
Supplement Date Received by Manufacturer08/24/2023
Initial Report FDA Received Date08/22/2023
Supplement Report FDA Received Date08/24/2023
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Date Device Manufactured01/08/2019
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention; Hospitalization;
Patient Age68 YR
Patient SexMale
Patient Weight147 KG
-
-